Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000050133
JPRN-UMIN000050133
Completed
未知

Effects of nitric oxide inhalation therapy in the percutaneous ventricular assist device (Impella). - Effects of nitric oxide inhalation therapy in the percutaneous ventricular assist device (Impella).

Iwate Medical University0 sites50 target enrollmentJanuary 30, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Iwate Medical University
Enrollment
50
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 30, 2023
End Date
January 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Under 20 years of age

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD)Implantation. - INOT41acute right ventricular failureMedDRA version: 9.1Level: LLTClassification code 10063082Term: Acute right ventricular failure
EUCTR2005-000326-24-DEINO Therapeutics110
Active, not recruiting
Phase 1
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD) Implantation. - INOT41
EUCTR2005-000326-24-GBINO Therapeutics110
Recruiting
Not Applicable
sefulness of Pulsed Inhaled Nitric OXide (iNO) in adults with asymptomatic or mildly symptomatic COVID patients without pre-existing illness.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases
CTRI/2021/05/033771Sir h n Reliance Foundation hospital and research centre
Active, not recruiting
Not Applicable
The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants.
EUCTR2004-002312-29-DEINO Therapeutics800
Active, not recruiting
Phase 1
The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. - INOT-27Prevention of chronic lung disease in pre-term infants ( gestational age < 29 weeks) with respiratory distress.MedDRA version: 7.0 Level: LLT Classification code 10054933
EUCTR2004-002312-29-GBINO Therapeutics800